Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Virology. 2021 May 14;560:43–53. doi: 10.1016/j.virol.2021.05.001

Figure 1: Treatment with immunosuppressants affects morbidity but not mortality or viremia in ZIKV-infected male mice.

Figure 1:

Study design (a). Survival curve of mice grouped by inoculum dose; 103 PFU: n = 28 (cyclophosphamide or PBS treated mice); 104 PFU: n=28 (other immunosuppressants or PBS treated mice) (b). Mouse weights were recorded daily (mean ± standard deviation) PBS: n=6; Cyclophosphamide: n = 11 (c). Mouse weights PBS: n=5; Dexamethasone: n=4; α-IFNAR antibody: n=4; Methylprednisolone acetate: n=4; Ketoconazole/Cyclosporine: n=4 (d). Infectious ZIKV in serum was quantified via plaque assay (e,f). Data points represent individual mice, horizontal lines represent group mean, and error bars represent standard deviation. Data were analyzed via repeated measures ANOVA.

* p<0.05; ** p<0.01; *** p<0.005; **** p<0.001.

Abbreviations: DPI, days post inoculation; IS, immunosuppression; LOD, limit of detection.